218 related articles for article (PubMed ID: 30641231)
21. Discriminating patients with early-stage pancreatic cancer or chronic pancreatitis using serum electrospray mass profiling.
Hocker JR; Postier RG; Li M; Lerner MR; Lightfoot SA; Peyton MD; Deb SJ; Baker CM; Williams TL; Hanas RJ; Stowell DE; Lander TJ; Brackett DJ; Hanas JS
Cancer Lett; 2015 Apr; 359(2):314-24. PubMed ID: 25637792
[TBL] [Abstract][Full Text] [Related]
22. Profiling of different pancreatic cancer cells used as models for metastatic behaviour shows large variation in their N-glycosylation.
Holst S; Belo AI; Giovannetti E; van Die I; Wuhrer M
Sci Rep; 2017 Nov; 7(1):16623. PubMed ID: 29192278
[TBL] [Abstract][Full Text] [Related]
23. Clinical significance of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in pancreatic ductal adenocarcinoma.
Waragai Y; Suzuki R; Takagi T; Sugimoto M; Asama H; Watanabe K; Kikuchi H; Hikichi T; Masamune A; Kang Y; Fleming JB; Ohira H
Pancreatology; 2016; 16(6):1044-1050. PubMed ID: 27665173
[TBL] [Abstract][Full Text] [Related]
24. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis.
Mayerle J; Kalthoff H; Reszka R; Kamlage B; Peter E; Schniewind B; González Maldonado S; Pilarsky C; Heidecke CD; Schatz P; Distler M; Scheiber JA; Mahajan UM; Weiss FU; Grützmann R; Lerch MM
Gut; 2018 Jan; 67(1):128-137. PubMed ID: 28108468
[TBL] [Abstract][Full Text] [Related]
25. Annexin A10 is a candidate marker associated with the progression of pancreatic precursor lesions to adenocarcinoma.
Zhu J; Wu J; Pei X; Tan Z; Shi J; Lubman DM
PLoS One; 2017; 12(4):e0175039. PubMed ID: 28369074
[TBL] [Abstract][Full Text] [Related]
26. ABO blood group IgM isoagglutinins interact with tumor-associated O-glycan structures in pancreatic cancer.
Hofmann BT; Stehr A; Dohrmann T; Güngör C; Herich L; Hiller J; Harder S; Ewald F; Gebauer F; Tachezy M; Precht C; Izbicki JR; Bockhorn M; Wagener C; Wolters-Eisfeld G
Clin Cancer Res; 2014 Dec; 20(23):6117-26. PubMed ID: 25320359
[TBL] [Abstract][Full Text] [Related]
27. Comparison of ILK and ERP29 expressions in benign and malignant pancreatic lesions and their clinicopathological significances in pancreatic ductal adenocarcinomas.
Zhang K; Yao H; Yang Z; Li D; Yang L; Zou Q; Yuan Y; Miao X
Clin Transl Oncol; 2016 Apr; 18(4):352-9. PubMed ID: 26887611
[TBL] [Abstract][Full Text] [Related]
28. RACK1 overexpression associates with pancreatic ductal adenocarcinoma growth and poor prognosis.
Li X; Xiao Y; Fan S; Xiao M; Wang X; Chen X; Li C; Zong G; Zhou G; Wan C
Exp Mol Pathol; 2016 Oct; 101(2):176-186. PubMed ID: 27498047
[TBL] [Abstract][Full Text] [Related]
29. Identification of 34 N-glycan isomers in human serum by capillary electrophoresis coupled with laser-induced fluorescence allows improving glycan biomarker discovery.
Schwedler C; Kaup M; Weiz S; Hoppe M; Braicu EI; Sehouli J; Hoppe B; Tauber R; Berger M; Blanchard V
Anal Bioanal Chem; 2014 Nov; 406(28):7185-93. PubMed ID: 25234305
[TBL] [Abstract][Full Text] [Related]
30. Quantitative glycoproteomics analysis reveals changes in N-glycosylation level associated with pancreatic ductal adenocarcinoma.
Pan S; Chen R; Tamura Y; Crispin DA; Lai LA; May DH; McIntosh MW; Goodlett DR; Brentnall TA
J Proteome Res; 2014 Mar; 13(3):1293-306. PubMed ID: 24471499
[TBL] [Abstract][Full Text] [Related]
31. Clinical Perspective on Proteomic and Glycomic Biomarkers for Diagnosis, Prognosis, and Prediction of Pancreatic Cancer.
Hanna-Sawires RG; Schiphuis JH; Wuhrer M; Vasen HFA; van Leerdam ME; Bonsing BA; Mesker WE; van der Burgt YEM; Tollenaar RAEM
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800786
[TBL] [Abstract][Full Text] [Related]
32. Glycoprotein biomarkers for the detection of pancreatic ductal adenocarcinoma.
Llop E; E Guerrero P; Duran A; Barrabés S; Massaguer A; José Ferri M; Albiol-Quer M; de Llorens R; Peracaula R
World J Gastroenterol; 2018 Jun; 24(24):2537-2554. PubMed ID: 29962812
[TBL] [Abstract][Full Text] [Related]
33. Quantitative Proteomic Analysis of Differentially Expressed Protein Profiles Involved in Pancreatic Ductal Adenocarcinoma.
Kuo KK; Kuo CJ; Chiu CY; Liang SS; Huang CH; Chi SW; Tsai KB; Chen CY; Hsi E; Cheng KH; Chiou SH
Pancreas; 2016 Jan; 45(1):71-83. PubMed ID: 26262590
[TBL] [Abstract][Full Text] [Related]
34. Autoantibody signature in human ductal pancreatic adenocarcinoma.
Tomaino B; Cappello P; Capello M; Fredolini C; Ponzetto A; Novarino A; Ciuffreda L; Bertetto O; De Angelis C; Gaia E; Salacone P; Milella M; Nisticò P; Alessio M; Chiarle R; Giuffrida MG; Giovarelli M; Novelli F
J Proteome Res; 2007 Oct; 6(10):4025-31. PubMed ID: 17824682
[TBL] [Abstract][Full Text] [Related]
35. Determination of Sialic Acid Isomers from Released
Manz C; Mancera-Arteu M; Zappe A; Hanozin E; Polewski L; Giménez E; Sanz-Nebot V; Pagel K
Anal Chem; 2022 Oct; 94(39):13323-13331. PubMed ID: 36121379
[TBL] [Abstract][Full Text] [Related]
36. Expression and prognosis value of SHP2 in patients with pancreatic ductal adenocarcinoma.
Zheng J; Huang S; Huang Y; Song L; Yin Y; Kong W; Chen X; Ouyang X
Tumour Biol; 2016 Jun; 37(6):7853-9. PubMed ID: 26695153
[TBL] [Abstract][Full Text] [Related]
37. Immune-complex level of cofilin-1 in sera is associated with cancer progression and poor prognosis in pancreatic cancer.
Satoh M; Takano S; Sogawa K; Noda K; Yoshitomi H; Ishibashi M; Mogushi K; Takizawa H; Otsuka M; Shimizu H; Miyazaki M; Nomura F
Cancer Sci; 2017 Apr; 108(4):795-803. PubMed ID: 28161904
[TBL] [Abstract][Full Text] [Related]
38. The Clinical and Pathological Significance of Nectin-2 and DDX3 Expression in Pancreatic Ductal Adenocarcinomas.
Liang S; Yang Z; Li D; Miao X; Yang L; Zou Q; Yuan Y
Dis Markers; 2015; 2015():379568. PubMed ID: 26294807
[TBL] [Abstract][Full Text] [Related]
39. Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.
Jin A; Xu Y; Liu S; Jin T; Li Z; Jin H; Lin L; Lin Z
Exp Mol Pathol; 2014 Feb; 96(1):54-60. PubMed ID: 24263054
[TBL] [Abstract][Full Text] [Related]
40. Proteomic analyses of ECM during pancreatic ductal adenocarcinoma progression reveal different contributions by tumor and stromal cells.
Tian C; Clauser KR; Öhlund D; Rickelt S; Huang Y; Gupta M; Mani DR; Carr SA; Tuveson DA; Hynes RO
Proc Natl Acad Sci U S A; 2019 Sep; 116(39):19609-19618. PubMed ID: 31484774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
